Important Note This article is for educational purposes only. Retatrutide is an investigational medicine and is not approved for use in the United Kingdom or most other countries. This content does not constitute medical advice.
The TRIUMPH programme is Eli Lilly’s large-scale Phase 3 clinical research effort evaluating retatrutide, an investigational triple receptor agonist. The programme includes multiple trials designed to assess the drug’s effects on body weight, metabolic health, cardiovascular outcomes, and long-term safety.
This page provides an educational summary of the TRIUMPH programme based on publicly available information as of mid-2026.
What is the TRIUMPH Programme?
The TRIUMPH programme consists of several Phase 3 clinical trials. Its main objectives include:
- Measuring changes in body weight
- Evaluating effects on blood sugar control
- Assessing cardiovascular and kidney outcomes
- Monitoring long-term safety and side effects
The programme is one of the most comprehensive efforts to evaluate a triple-agonist peptide to date.
Key TRIUMPH Trials
| Trial Name | Focus Area | Key Objectives | Status (as of mid-2026) |
|---|---|---|---|
| TRIUMPH-1 | Obesity / Overweight | Weight loss efficacy and safety | Topline results released |
| TRIUMPH-2 | Type 2 diabetes | Effects on blood sugar and weight | Ongoing |
| TRIUMPH-3 | Cardiovascular outcomes | Heart and blood vessel health | Ongoing |
| TRIUMPH-4 | Osteoarthritis with obesity | Effects on joint pain and physical function | Results released |
| TRIUMPH-Outcomes | Long-term cardiovascular & kidney | Major heart and kidney events | Ongoing |
Each trial involves different participant groups and specific goals, aiming to provide a broad understanding of retatrutide’s potential benefits and risks.
What Have the Trials Shown So Far?
Early results from the TRIUMPH programme have been notable:
- TRIUMPH-1: Topline results showed significant average weight loss, with some doses associated with reductions approaching 28–29% over 68 weeks.
- TRIUMPH-4: Demonstrated improvements in both body weight and physical function among participants with obesity and knee osteoarthritis.
Other trials in the programme are still ongoing. Full peer-reviewed results and detailed analyses are expected in the coming periods. Regulatory submission is anticipated after key studies are completed, though retatrutide remains investigational as of July 2026.
How Long Do the Trials Last?
Most trials in the TRIUMPH programme range from 68 to 88 weeks in duration. Some include extension studies to gather longer-term data on safety and weight maintenance after the main treatment period.
Current Status (July 2026)
As of mid-2026:
- Some trials have released topline or interim results.
- Several trials are still ongoing.
- Regulatory submission is expected after completion of key studies.
- Retatrutide remains an investigational medicine and is not approved in the UK or other major markets.
Why These Trials Matter
The TRIUMPH programme represents one of the largest and most structured efforts to evaluate a triple-agonist peptide. The results may help determine whether retatrutide could become a future treatment option for obesity and related conditions. However, it cannot be considered an approved treatment until full data is published and reviewed by regulatory authorities.
Summary
The TRIUMPH programme is evaluating retatrutide across multiple Phase 3 trials focusing on weight loss, metabolic effects, cardiovascular outcomes, and long-term safety. Early results have shown substantial average weight loss in some studies, but retatrutide remains investigational as of July 2026. More comprehensive data is expected in the coming periods.
References
- ClinicalTrials.gov – TRIUMPH Programme (Eli Lilly). NCT05929066 and related entries.
- Eli Lilly and Company. (May 2026). Lilly’s triple-agonist retatrutide delivered powerful weight loss in Phase 3 TRIUMPH-1 trial. Press Release.
- Jastreboff, A.M. et al. (2022). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.
- Medicines and Healthcare products Regulatory Agency (MHRA) – Guidance on investigational medicines.
.For more information, see our main guide on Side Effects and Safety of Retatrutide
Last Updated: July 2026